

Contents

Contributors	xiii
-------------------------------	------

Preface

<i>Avshalom Mizrahi</i>	xv
-----------------------------------	----

Human Monoclonal Antibodies: Their Potential, Problems, and Prospects

Janice E. Boyd and Keith James

I. General Strategies Used in Human Monoclonal Antibody Production	2
A. Sources of Lymphocytes	2
B. In Vitro Immunization	4
C. Procedures for Immortalizing Human B Cells	7
D. Cloning and Expansion of Antibody-Secreting Cell Lines	9
1. Production of Antibody In Vivo	9
2. Production of Antibody In Vitro	20
II. A Survey of Available Human Monoclonals and Their Uses	21
III. Limitation of Current Technologies	25
IV. Future Strategies	26
A. Conventional Approaches	26
B. Genetic-Engineering Techniques	28

Equipment and Procedures for Production of Monoclonal Antibodies in Culture

S. Reuveny and A. Lazar

I. Factors Affecting Monoclonal Antibody Production	47
A. Kinetics of Antibody Production	47
B. Growth Media	49
C. Environmental Factors	52
D. Antibody Production Rate	52
E. Antibody Stability	53
F. Shear Sensitivity of Hybridoma Cells	54
II. Systems of Production of Monoclonal Antibodies	57
A. Batch and Modified Batch Cultures	57
B. Continuous Cultures	60
C. Perfusion Systems	62
1. Homogeneous Perfusion Systems	63
2. Semihomogeneous Perfusion Systems (Microencapsulation)	65
3. Nonhomogeneous Perfusion Systems	67
a. Hollow-Fiber Reactors	67
b. Flat Membrane Reactors	69
c. Ceramic Matrix Reactors	70
d. Fixed-Bed Reactors	71
e. The Static Maintenance Reactor	72
III. Future Directions in Monoclonal Antibody Technology	73

Stirred Tank Perfusion Reactors for Cell Propagation and Monoclonal Antibody Production

Jerry Shevitz, Shaul Reuveny, Thomas L. LaPorte, and Gyu Heon Cho

I. Reactor Design Considerations	83
A. Nonhomogeneous Systems	83
B. Homogeneous Systems	83
II. Stirred Reactors	85
A. Shear Sensitivity of Animal Cells	85
B. Agitation Systems	86
C. pH Control	89
D. Dissolved Oxygen Control	90
III. Batch Cultures	93
IV. Perfusion Cultures	94
A. Perfusion	94
B. Perfusion Maintenance	95
C. Automated System to Control Cell Density	97
V. Media	99
VI. Productivity	101
VII. Concluding Remarks	102

Serum-Free Media Used for Cultivation of Hybridomas

Hiroki Murakami

I. General Remarks Regarding Preparation of Serum-Free Medium	108
II. Basal Media for Serum-Free Culture	111
III. Serum-Free Media Formulated by Supplementation With Growth Factors and Other Supplements	113
IV. Commercial Production of Serum-Free Media for Hybridoma Culture	122
V. Detoxification of Cytotoxic Metabolites	122
VI. Freezing of Hybridoma Cells in Serum-Free Medium	125
VII. High-Density Culture of Hybridoma Cells	127
A. Suspension Culture of Hybridoma Cells	127
B. Membrane Culture of Hybridoma Cells	132
VIII. Productivity of Monoclonal Antibodies in Serum-Free Medium	132
IX. Further Directions	133

Large-Scale Purification of Monoclonal Antibodies

Andrew C. Kenney

I. Special Requirements of Production Separation Systems	144
A. Aims of Production Versus Laboratory Separations	144
B. Regulatory Considerations	145
C. Environmental Considerations	145
D. Engineering Considerations	146
E. Performance Considerations	147
II. Choice of Unit Processes	147
A. The Sequence of Steps	147
B. Primary Recovery	148
C. Chromatography	150
1. High vs. Low Pressure	150
2. Ion Exchange	150

3. IgM Purification	152
4. Large-Scale Ion Exchange	152
5. Protein A Chromatography	153
III. Conclusions	155

High Performance Liquid Chromatography and Related Methods in Purification of Monoclonal Antibodies

Alois Jungbauer and Elisabeth Wenisch

I. General Remarks	163
A. Application of Monoclonal Antibodies	163
1. Affinity Ligands	163
2. Diagnostic and Research Tools	163
3. Therapeutic Use and In Vivo Imaging	164
B. What is HPLC?	164
II. Background	165
A. Chromatographic Modes in Preparative Chromatography	165
1. The Concentration Mode	165
2. The Purification Mode	166
3. Negative Purification	167
4. Analytical Mode	167
B. The Starting Material	167
1. Ascites Fluid	168
2. Hybridoma Culture Supernatant	168
C. Equipment for HPLC and Related Methods for the Purification of Monoclonal Antibodies	169
1. Pumps and Mixing Device	171
2. Detectors	171
3. Fraction Collectors	171
III. Selected Methods for the Purification of Monoclonal Antibodies	172
A. Ion-Exchange Chromatography	172
1. Selecting the Buffer Conditions for the Ion-Exchange Chromatography	172
2. Methods for Purification of Mabs From Ascites Fluid	173
3. Methods for Purification of Mabs From Culture Supernatant	174
B. Hydrophobic Interaction Chromatography	178
1. Experimental Procedures in Hydrophobic Interaction Chromatography	178
2. Selected Methods of Mab Purification	178
C. Protein A Columns	181
1. Experimental Procedure for Protein A HPLC	182
2. Examples of Protein A in Mab Purification	182
D. Hydroxylapatite	182
E. Immunoaffinity Chromatography	183
a. Preactivated HPLC Support for Coupling of Antigen and Antibody	186
F. Pseudo-Affinity and Affinity Chromatography	186
G. Gel Permeation Chromatography	187
H. Miscellaneous Methods for Mab Purification Using HPLC	187
1. Thiophilic Adsorption of Immunoglobulins	187
2. Chromatofocusing	187
3. Reversed Phase Chromatography (RPC)	188
J. Purification of Monoclonal IgM by HPLC and Related Methods	188
IV. Quality Control of Mabs	188
V. Conclusions and Future Prospects	189

Immunotoxins: Monoclonal Antibody-Toxin Conjugates—A New Approach to Cancer Therapy

J. Michael Lord, Robert A. Spooner, and Lynne M. Roberts

I. Toxins	194
A. Bacterial Toxins	194
B. Plant Toxins	197
1. Cytotoxic Lectins	197
2. Ribosome Inactivating Proteins	199
II. Antibodies	199
III. Preparation of Immunotoxins	200
IV. Cytotoxicity of Immunotoxins	200
V. Experimental Evaluation of Immunotoxins	203
VI. Limitations and Prospects	204

Use of Monoclonal Antibodies in Immunodiagnostic Systems

L. Wang, H. Ben-Bassat, and M. Inbar

I. Hormones and Vitamins	216
A. Endocrine Hormones	216
B. Thyroid Function Hormones	218
C. Other Hormones	220
D. Vitamins	220
II. Tissue and Cellular Antigens	220
A. Phenotyping of Hematopoietic Cells	220
B. Oncofetal Antigens	222
C. Tissue Antigens	224
D. Miscellaneous	226
III. Therapeutic Drug Monitoring	226
A. Theophylline	227
B. Digoxin	227
C. Anti-Epileptic Drugs	228
D. Anti-Arrhythmic Drugs	229
E. Cyclosporine	229
F. Other Drugs	229
IV. Microbiology	230
A. Viruses	231
1. Hepatitis	231
2. Rota Virus	233
3. Herpes Simplex Virus	233
4. Influenza Virus	233
5. Cytomegalovirus	234
6. Respiratory Syncytial Virus	234
7. Rubella Virus	235
8. Rabies	235
9. Human Immunodeficiency Virus	235
10. Other Viruses	236
B. Bacteria	236
1. Enterotoxigenic <i>Escherichia coli</i> and <i>Vibrio cholera</i>	237
2. <i>Shigella</i> and Enteroinvasive <i>E. coli</i> (EIEC)	238
3. <i>Salmonella</i>	238
4. <i>Clostridium</i>	240

5. <i>Corynebacteria</i>	240
6. <i>Campylobacter</i>	241
7. <i>Streptococcus</i>	241
8. <i>Staphylococcus</i>	243
9. <i>Mycobacteria</i>	243
10. <i>Neisseria</i>	244
11. <i>Treponema</i>	245
12. <i>Bacteroides</i>	245
13. <i>Hemophilus</i>	246
14. <i>Legionella</i>	246
C. Parasites	247
1. Chlamydiae	247
2. Blood and Tissue Protozoa	247
3. Intestinal and Urogenital Protozoa	248
4. Intestinal Helminths	248
5. Bancroftian	249
6. Yeast	249
V. Immunoglobulins and Allergy	249
A. Immunoglobulins	249
1. Immunoglobulin G	249
2. Immunoglobulin M	250
3. Immunoglobulin D	250
4. Immunoglobulin A	250
5. Autoimmune Diseases	250
B. Allergy	251
VI. Enzymes and Isozymes	252
A. Creatine Kinase	253
B. Alkaline Phosphatase	253
1. Placental Alkaline Phosphatase	253
2. Intestine Alkaline Phosphatase	255
3. Liver-Bone-Kidney-Type Alkaline Phosphatase	255
C. Acid Phosphatase	256
D. Alpha-Amylase	256
E. Lipase	257
F. Acetylcholine Esterase	257
G. Gamma-Enolase	257
H. Plasminogen Activator	258
I. Other Enzymes	258
VII. Growth Factors and Serum Proteins	259
A. Interleukins	259
B. Interferons	260
C. Ferritin	262
D. Glycosylated Hemoglobin	263
E. Fibrin	263
F. Lipoproteins	264
1. Apolipoprotein A (Apo A)	264
2. Apolipoprotein B (Apo B)	264
3. Apolipoprotein C	265
4. Apolipoprotein D	266
5. Apolipoprotein E	266
G. Miscellaneous	266
VIII. Concluding Remarks	266

5. <i>Corynebacteria</i>	240
6. <i>Campylobacter</i>	241
7. <i>Streptococcus</i>	241
8. <i>Staphylococcus</i>	243
9. <i>Mycobacteria</i>	243
10. <i>Neisseria</i>	244
11. <i>Treponema</i>	245
12. <i>Bacteroides</i>	245
13. <i>Hemophilus</i>	246
14. <i>Legionella</i>	246
C. Parasites	247
1. Chlamydiae	247
2. Blood and Tissue Protozoa	247
3. Intestinal and Urogenital Protozoa	248
4. Intestinal Helminths	248
5. Bancroftian	249
6. Yeast	249
V. Immunoglobulins and Allergy	249
A. Immunoglobulins	249
1. Immunoglobulin G	249
2. Immunoglobulin M	250
3. Immunoglobulin D	250
4. Immunoglobulin A	250
5. Autoimmune Diseases	250
B. Allergy	251
VI. Enzymes and Isozymes	252
A. Creatine Kinase	253
B. Alkaline Phosphatase	253
1. Placental Alkaline Phosphatase	253
2. Intestine Alkaline Phosphatase	255
3. Liver-Bone-Kidney-Type Alkaline Phosphatase	255
C. Acid Phosphatase	256
D. Alpha-Amylase	256
E. Lipase	257
F. Acetylcholine Esterase	257
G. Gamma-Enolase	257
H. Plasminogen Activator	258
I. Other Enzymes	258
VII. Growth Factors and Serum Proteins	259
A. Interleukins	259
B. Interferons	260
C. Ferritin	262
D. Glycosylated Hemoglobin	263
E. Fibrin	263
F. Lipoproteins	264
1. Apolipoprotein A (Apo A)	264
2. Apolipoprotein B (Apo B)	264
3. Apolipoprotein C	265
4. Apolipoprotein D	266
5. Apolipoprotein E	266
G. Miscellaneous	266
VIII. Concluding Remarks	266

Monoclonal Antibodies in Cancer Diagnosis and Therapy*Nava Epstein, Ellen Warner-Efrati, and Raphael Catane*

I. Tumor-Associated Antigens (TAAs)	306
A. Definition and Main Features	206
B. TAAs as Tumor Markers	307
C. Specificity of Monoclonal Antibodies to TAAs	308
II. Uses of Monoclonal Antibodies in Diagnosis of Malignancies	308
A. In Vitro Diagnosis	308
1. Detection of Tumor Antigens in Blood or Other Body Fluids	309
2. Detection of Tumor Antigens in Tissue Sections	309
B. In Vivo Diagnosis	309
1. Radioimmunoimaging of Immunoscintigraphy	311
III. Use of Monoclonal Antibodies for Therapy	311
A. In Vitro Therapy (Use in Bone Marrow Transplantation)	311
1. Removal of Tumor Cells (Bone Marrow Purging)	311
2. Removal of Normal T Lymphocytes to Prevent Graft-Versus-Host Disease	312
B. In Vivo Therapy	312
1. Unconjugated Monoclonal Antibodies (Mabs)	317
2. Conjugated Monoclonal Antibodies	319
C. Use of Anti-Idiotypic Antibodies for Active Immunotherapy	320
IV. Human Monoclonal Antibodies	320
V. Conclusions and Future Prospects	320

Monoclonal Antibodies as New Antitumor Agents*Thomas W. Griffin, Mary Ellen Rybak, and Lisa Giordano*

I. Systemic Nature of Cancer	335
II. Tumor-Associated Antigens and Monoclonal Antibodies	337
A. Oncofetal Proteins	337
B. Growth Factor Receptors	339
C. Differentiation Antigens	340
D. Oncogene Products	341
III. Monoclonal Antibodies as Antitumor Agents	341
A. Unconjugated Antibodies	341
1. Mechanisms of Tumor-Cell Killing	344
2. Problems With Monoclonal Antibody Therapy	344
3. Bone Marrow Purging With Monoclonal Antibodies	344
B. Antibody Conjugates	344
1. Types	345
2. Radioimmunoconjugates	347
IV. Future Prospects	347
A. Clinical Trials With Monoclonal Antibodies	350
B. Trials With Unconjugated Antibodies	351
C. Trials With Radioimmunoconjugates	351

Monoclonal Antibodies as Catalysts and Templates for Organic Chemical Reactions*Bernard S. Green*

I. Background	361
A. History and Development	361
B. Approach and Rationale	367

II. Recent Results	369
A. Antibody-Promoted Hydrolysis	369
B. Antibody-Catalyzed Hydrolysis	373
C. Asymmetric Synthesis	377
D. Templates for Chemical Reactions	378
1. Restriction of Molecular Conformation	378
2. Intermolecular Interactions	380
III. Future Directions	381
A. Expanded Scope of Chemical Reactions	381
B. Correlation of Hapten Structure and Reaction Catalyzed	382
C. Metal Ion and Other Cofactors	383
D. Chemically Modified Antibodies	383
E. Combination Antibody-Chemical Systems	384
F. Site-Directed Mutagenesis	385
G. Anti-Anti-Enzyme Antibodies	385
IV. Biotechnological Implications	385
V. Medical Implications	386
VI. Summary	386
Index	395
Contents of Previous Volumes	413